<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224392</url>
  </required_header>
  <id_info>
    <org_study_id>RectumSIB</org_study_id>
    <nct_id>NCT01224392</nct_id>
  </id_info>
  <brief_title>Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer</brief_title>
  <acronym>RectumSIB</acronym>
  <official_title>Randomized Trial of Preoperative Radiotherapy With an Integrated Simultaneous Boost Compared to Chemoradiotherapy for T3-4 Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized non-inferiority trial that compares preoperative
      Fluoro Uracil (FU)-based chemoradiotherapy to radiotherapy with a simultaneous integrated
      boost. In patients with T3-4 rectal cancer, the latter approach is considered preferential
      with regard to toxicity and cost. The metabolic response of the tumor, as assessed by
      18F-2-Fluoro-2-Deoxyglucose-Positron Emission tomography (18F-FDG PET) or PET-CT, will be
      used as a surrogate marker of cause specific outcome
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in metabolic tumor activity</measure>
    <time_frame>at baseline and at 5 to 6 weeks after neo-adjuvant therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>histological downgrading (Dworak classification)</measure>
    <time_frame>after the rectum surgery</time_frame>
    <description>pathological evaluation of surgical resection specimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of R0, R1 and R2 resections</measure>
    <time_frame>after the rectum surgery</time_frame>
    <description>pathological evaluation of surgical resection specimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute and late toxicity, according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</measure>
    <time_frame>at baseline, every 6 months after completion of radiotherapy and then yearly until 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>every 6 months in the first year after completion of radiotherapy and then yearly until 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>every 6 months in the first year after completion of radiotherapy and then yearly until 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>every 6 months in the first year after completion of radiotherapy and then yearly until 3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at baseline, every 6 months in the first year after completion of radiotherapy and then yearly until 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost evaluation</measure>
    <time_frame>during the treatment and follow-ups</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Concomitant chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends</description>
    <arm_group_label>Concomitant chemoradiotherapy</arm_group_label>
    <other_name>Xeloda (capecitabine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with boost</intervention_name>
    <description>Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor</description>
    <arm_group_label>Radiotherapy with boost</arm_group_label>
    <other_name>Preoperative radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histopathologically confirmed rectal adenocarcinoma with an inferior border within 15
             cm of the anal verge

          -  the tumor has to have evidence of T3 or T4 disease on Magnetic Resonance Imaging (MRI)
             or endoluminal ultrasound

        Exclusion Criteria:

          -  unresectable metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 3

          -  patients not deemed fit for radiotherapy, capecitabine or surgery

          -  pregnant or lactating patients

          -  women with child bearing potential who lack effective contraception

          -  patients below 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark De Ridder, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark De Ridder, Prof.Dr.</last_name>
    <phone>+3224776147</phone>
    <email>mark.deridder@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harijati Versmessen, MD</last_name>
    <phone>+3224763407</phone>
    <email>harijati.versmessen@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel , Vrije Universiteit Brussel, dienst Radiotherapie</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>9010</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark De Ridder, Ph.D</last_name>
      <phone>+3224776147</phone>
      <email>mark.deridder@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Harijati Versmessen, MD</last_name>
      <phone>+3224763407</phone>
      <email>harijati.versmessen@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Mark De Ridder, Prof., Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Engels Benedikt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark De Ridder, Prof.Dr.</last_name>
      <phone>+3224776147</phone>
      <email>mark.deridder@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Harijati Versmessen, MD</last_name>
      <phone>+3224763407</phone>
      <email>harijati.versmessen@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Mark De Ridder, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benedikt Engels, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Mark De Ridder</investigator_full_name>
    <investigator_title>Head of Radiotherapy Department</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>colorectal neoplasms</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>T3-4 rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

